Website
News25/Ratings1
Price$1.95-0.85 (-30.46%)
2026-01-202026-04-23
News · 26 weeks26-57%
2025-10-262026-04-19
Mix1990d
- SEC Filings10(53%)
- Other9(47%)
Latest news
25 items- SECSEC Form PRE 14A filed by Bluejay Diagnostics Inc.PRE 14A - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical TrialACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. ("Bluejay" or the "Company"), a medical diagnostics company focused on rapid, near-patient testing, today announced the successful enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the Company's Symphony™ platform for interleukin-6 (IL-6) testing in critical care settings to determine patient acuity for sepsis triage and monitoring. The SYMON-II study has a target enrollment of 750 patients, and the Company expects to complete enrollment within the next 2 to 3 months, subject to site activity and patient flow. Importantly, the study's inclusion and exclusion criteria hav
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual MeetingACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests for critical care conditions, today announced that an abstract related to its Symphony™ IL-6 Test has been accepted for presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting, which will take place May 18–21, 2026 in Atlanta, Georgia. The presentation will report findings from SYMON-I, a multicenter pilot clinical study evaluating interleukin-6 (IL-6) levels in patients with sepsis who were admitted or intended for admission to the intensive care unit (ICU). The analysis evalu
- SECSEC Form 10-K filed by Bluejay Diagnostics Inc.10-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Diagnostics Provides Corporate Update and 2026 Strategic OutlookACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today provided a corporate update highlighting recent progress and its planned strategic trajectory through 2026. Operational and Clinical ProgressBluejay continues to advance its Symphony™ platform, including the Company's lead product candidate for the rapid measurement of Interleukin-6 (IL-6) to support sepsis risk assessment and critical-care decision making. The Company confirmed that its SYMON™ II clinical study is progressing as planned, with on
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Diagnostics Announces All Prefunded Warrants Now ExercisedACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ:BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants of any class or tranche outstanding. Following these exercises, the Company now has approximately 972,000 shares of common stock outstanding. In addition, the Company has cash exercisable warrants outstanding for approximately 1.5 million shares. All such warrants have a cash exercise price of $7.00 or greater per share. The Company notes that several recent Schedule 13G filings made by investors
- SECSEC Form SCHEDULE 13G filed by Bluejay Diagnostics Inc.SCHEDULE 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECSEC Form SCHEDULE 13G filed by Bluejay Diagnostics Inc.SCHEDULE 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)
- PRBluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ:BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial progress in advancing manufacturing readiness and technology transfer initiatives into 2026, representing a key execution milestone as the Company transitions from clinical enrollment toward data analysis, regulatory engagement, and commercialization readiness. SYMON-II Clinical trialsBluejay is successfully enrolling across all participating sites in its SYMON™ II multicenter IL-6 monitoring study, with a total of 545 patients enrolled with a target of 750 patients, exceeding i
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bluejay Diagnostics Inc.SCHEDULE 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Diagnostics Announces 1-for-4 Reverse Stock SplitACTON, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-4 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on January 29, 2026, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on January 29, 2026 under the Company's existing trading symbol, "BJDX." A
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody ProductionACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company") announced that it has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), a biomarker relevant to inflammatory and critical-care applications. The Company stated that both polyclonal and monoclonal antibodies met internal performance criteria, including reactivity, for use in Symphony™ cartridge manufacturing intended for clinical and potential future commercial applications. Bluejay has generated polyclonal antibodies using both third-party and internally developed immunogens. The Company intends to utilize an
- SECSEC Form EFFECT filed by Bluejay Diagnostics Inc.EFFECT - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECSEC Form 424B3 filed by Bluejay Diagnostics Inc.424B3 - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic PartnershipsCompany focused on advancing clinical milestones and strategic partnerships, with goal of positioning itself for future FDA clearance and product commercialization.Patient enrollment in SYMON-II clinical trial now approximately 50% completed.Recent private placement transaction completed in October 2025; Company continues to explore further financing opportunities. ACTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing near-patient testing solutions for critical care, announced financial results for the quarter ended September 30, 2025, and highlighted continued progress across its clin